A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD (SATURN)
Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in Neuromyelitis Optica Spectrum Disorder: A Multicenter Prospective Cohort Study
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Xixi Yang, MD, PhD
- Telefonnummer: +86 15601179281
- E-mail: xyang891@outlook.com
Undersøgelse Kontakt Backup
- Navn: Zheng Liu, MD, PhD
- Telefonnummer: +86 13754093891
- E-mail: lzwcy@xwhosp.org
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100053
- Rekruttering
- Xuanwu Hospital Capital Medical University
-
Kontakt:
- Xixi Yang, MD, PhD
- Telefonnummer: +8615601179281
- E-mail: xyang891@outlook.com
-
Kontakt:
- Zheng Liu, MD, PhD
- Telefonnummer: +8613754093891
- E-mail: xyang891@outlook.com
-
Underforsker:
- Xixi Yang, MD, PhD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Diagnosis of AQP4-IgG-positive NMOSD* and age ≥ 18 years; EDSS score ≤ 8.5 during an acute relapse in NMOSD patients; NMOSD patients experiencing an acute relapse who are scheduled to receive or are currently receiving recommended acute-phase treatments-including intravenous methylprednisolone, IVIG, PE, or PA; Receiving Satralizumab treatment; Patient understands the study procedures and has signed the informed consent form indicating willingness to participate in the study.
Exclusion Criteria:
- Patients with NMOSD who received other biologics (e.g., rituximab, inebilizumab, tocilizumab, eculizumab) either within the past 6 months prior to this acute exacerbation or during the current acute phase; Patients with contraindications to Satralizumab, including: known allergy to Satralizumab or any inactive ingredient, active Hepatitis B infection, active or therapy-naive latent tuberculosis; Pregnant or lactating women; Patients with concomitant Neoplasm malignant or other severe diseases; Patients currently enrolled in other interventional clinical studies; Patients assessed by the investigator/research staff as having a Critical illness or any Mental disorder or Cognitive disorder that may interfere with the study and who are unable to complete the key assessments required by this protocol; patients assessed by the investigator/research staff as unlikely to attend scheduled follow-up assessments under routine clinical care.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Satralizumab Treatment Group
NMOSD patients receiving Satralizumab at early phase of an NMOSD attack
|
As recommended in the prescribing information, patients will receive subcutaneous satralizumab Injection as part of their routine treatment.
The loading dose is 120 mg administered at Weeks 0, 2, and 4, followed by a maintenance dose of 120 mg every 4 weeks.
Maintenance treatment is recommended for a minimum duration of 24 weeks.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
EDSS
Tidsramme: 24 weeks
|
Change in EDSS score between at baseline and at 6 months of treatment
|
24 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
EDSS
Tidsramme: 12 weeks
|
Change in EDSS score between at baseline and at 3 months of treatment
|
12 weeks
|
|
mRS
Tidsramme: 12 weeks
|
Changes in mRS between at baseline and at 3 months of treatment
|
12 weeks
|
|
EQ-5D
Tidsramme: 12 weeks
|
Changes in EQ-5D between at baseline and at 3 months of treatment
|
12 weeks
|
|
ADL score
Tidsramme: 12 weeks
|
Changes in ADL score between at baseline and at 3 months of treatment
|
12 weeks
|
|
mRS
Tidsramme: 24 weeks
|
Changes in mRS between at baseline and at 6 months of treatment
|
24 weeks
|
|
EQ-5D
Tidsramme: 24 weeks
|
Changes in EQ-5D between at baseline and at 6 months of treatment
|
24 weeks
|
|
ADL score
Tidsramme: 24 weeks
|
Changes in ADL score between at baseline and at 6 months of treatment
|
24 weeks
|
|
relapse
Tidsramme: 24 weeks
|
Relapse events occurring within 6 months of treatment
|
24 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Junwei Hao, MD, PhD, Xuanwu Hospital Department of Neurology
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Øjensygdomme
- Demyeliniserende autoimmune sygdomme, CNS
- Autoimmune sygdomme i nervesystemet
- Demyeliniserende sygdomme
- Myelitis, tværgående
- Optisk neuritis
- Synsnervesygdomme
- Sygdomme i kranienerve
- Neuromyelitis Optica
- Saturralizumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- xw-[2025]291-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .